MAPK1 and Alzheimer disease: Although early evidence suggested that ERK2 activity in the Tg2576 AD model was attenuated only at 20 months of age (Dineley et al, 2001), here we show significantly diminished ERK phosphorylation at 7 months of age that is rescued by ERK‐enhancing treatment.